ABBV
AbbVie Inc$197.69 ▲
+0.16% (+0.31)
Technical Indicators
Day Summary
Open $198.67
High $199.18
Low $196.44
Prev Close $197.38
Company News
Should You Buy AbbVie Stock Hand Over Fist Before April 29?
AbbVie (ABBV) To Report Earnings Tomorrow: Here Is What To Expect
AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata
Kestrel Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, in Patients with KRAS-driven Malignancies
RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF inhibitor
EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie
ValuEngine Weekly Market Summary And Commentary
Rinvoq demonstrated superiority versus Humira for primary endpoint in rheumatoid arthritis study
AbbVie Files Application With FDA For Upadacitinib To Treat Adults, Adolescents With Severe Alopecia Areata
